Manufacturer Supply, High Purity, Commercial Production
| Chemical Name |
2-(Chloromethyl)-3-Methyl-4-(2,2,2-Trifluoroethoxy)pyridine Hydrochloride |
| Synonyms |
Lansoprazole Chloride Compound; Lansoprazole Intermediate 1 |
| CAS Number |
127337-60-4 |
| CAT Number |
RF-PI1917 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C9H9ClF3NO·HCl |
| Molecular Weight |
276.08 |
| Melting Point |
208.0~214.0℃ |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White Crystalline Powder |
| Identification |
IR; HPLC |
| Loss on Drying |
<0.50% |
| Residue on Ignition |
<0.20% |
| Related Substances |
|
| Individual Impurity |
<0.50% |
| Total Impurities |
<0.50% |
| Heavy Metals |
<10ppm |
| Assay |
98.0~102.0% (HPLC, on dried basis) |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Lansoprazole (CAS: 103577-45-3)
|
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Lansoprazole Chloride Compound (CAS: 127337-60-4) is an intermediate for Lansoprazole (CAS: 103577-45-3). Lansoprazole is a proton pump inhibitor (PPI) similar to Omeprazole that inactivates the hydrogen/potassium-stimulated ATPase pumps in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH. It is a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. Dexlansoprazole is an isomer of lansoprazole that has a similar spectrum of activity and toxicities. Lansoprazole is a prescription medicine used to treat: gastroesophageal reflux disease (GERD); erosive esophagitis; stomach ulcers; duodenal ulcers; H. Pylori infections; Zollinger-Ellison syndrome. The Lansoprazole molecule is off-patent and so generic drugs are available under many brand names in many countries; there are patents covering some formulations in effect as of 2015.